Evaluation of low level laser therapy versus topical steroids in management of symptomatic oral lichen planus by detecting the level of salivary interleukin-6: Controlled clinical trial

Abdel Rahman Abuelmajd Aburehab Ibrahim; Hala Kamal Abdel Gaber; Olfat Gamil Shaker; Mohamed Wagdy Bissar

doi:10.53730/ijhs.v7nS1.14486

Authors

Abdel Rahman Abuelmajd Aburehab Ibrahim
abdoforme2@gmail.com
MSc candidate at the Department of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Dentistry, Ain Shams University, Egypt
Hala Kamal Abdel Gaber Professor of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Dentistry, Ain Shams University, Egypt
Olfat Gamil Shaker Professor of Medical Biochemistry, Faculty of Medicine, Cairo University, Egypt
Mohamed Wagdy Bissar Assistant Professor of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Dentistry, Ain Shams University, Egypt

Keywords:

low level laser therapy, interleukin-6, oral lichen planus, biomarkers

Abstract

Background: Oral lichen planus (OLP) is a relatively common chronic inflammatory immune-mediated disease affecting the oral mucosa with episodes of exacerbations and remissions. The current study was aimed to compare between the therapeutic outcomes of using low level laser therapy (LLLT) and topical steroids in management of symptomatic OLP and to correlate between the salivary levels of interleukin-6 (IL-6) in in relation to the clinical scores (CS) and pain visual analogue scores (P-VAS) before and after treatment. Subjects and methods: 40 participants were included in this study and were divided into 4 groups of 10 participants each. Group (I) included ten symptomatic atrophic or erosive OLP patients and received topical steroid (triamcinolone acetonide 0.1%). Group (II) comprised also of ten patients having symptomatic OLP and managed with LLLT using 810 nm diode laser. Group (III) included ten patients with asymptomatic reticular OLP. Group (IV) included ten healthy volunteers having no oral or skin lichen planus lesions.

Downloads

Download data is not yet available.

References

Al-Hashimi I., Schifter M., Lockhart P.B., Wray D. & Brennan M., 2007. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 103(25):1-12.

Sousa F.A. & Rosa L.E., 2008. Oral lichen planus: clinical and histopathological considerations. Brazilian Journal of Otorhinolaryngology, 74(2): 284-292.

Silverman S.J. & Bahl S., 1997. Oral lichen planus update: clinical characteristics, treatment responses, and malignant transformation. American Journal of Dentistry, 10(6):259-263.

Gorouhi F., Davari P. & Fazel N., 2014. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. The Scientific World Journal, 74(2):826-831.

Mutafchieva M.Z., Dragonova-Filipova M.N., Zagorchev P.I. & Tomov G.T., 2018. Oral lichen planus - Known and unknown: a review. Folia Medica, 60(4):528535.

Chainani-Wu N., Silverman S.J., Lozada-Nur F., Mayer P. & Watson J.J., 2015. Oral lichen planus: patient profile, disease progression and treatment responses. Journal of the American Dental Association, 132(1):901909.

Nosratzehi T., 2018. Oral Lichen Planus: An Overview of Potential Risk factors, Biomarkers and treatment. Asian Pacific Journal of Cancer Prevention: APJCP, 19(5):1161-1167.

Humberto J.S.M., Pavanin J.V., Rocha M.J. & Motta A.C., 2018. Cytokines, cortisol and nitric oxide as salivary biomarkers in oral lichen planus: a systematic review. Brazilian Oral Research, 32(1):82-89.

Zhang L., Jiang J., Arellano M., Zhang L., & Shen H.U., 2008. Quantification of Serum Proteins of Metastatic Oral Cancer Patients Using LCMS/MS and iTRAQ Labeling. The Open Proteomics Journal, 1:72-78.

Lavanya N., Jayanthi P., Rao U.K., and Ranganathan K., 2011. Oral lichen planus: An update on pathogenesis and treatment. Journal of Oral and Maxillofacial Pathology, 15(2):127-133.

Patil S., Khandelwal S., Sinha N., Kaswan S., Rahman F. & Tipu S., 2016. Treatment modalities of oral lichen planus: an update. Journal of Oral Diagnosis 1(1): 116-121.

Singh N., Rieder M.J. & Tucker M.J., 2004. Mechanisms of glucocorticoid- mediated anti- inflammatory and immunosuppressive action. Paediatric and Perinatal Drug Therapy, 6(2): 107-115.

Dillenburg C.S., Martins M.A., Munerato M.C., Marques M.M., & Martins M.D., 2014. Efficacy of laser phototherapy in comparison to topical clobetasol for the treatment of oral lichen planus: a randomized controlled trial. Journal of Biomedical Optics, 19(6):80-92.

Swift J.C., Rees T.D., Plemons J.M., Hallmon W.W. & Wright J.C., 2005. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. Journal of periodontology, 76(4):627-635.

ElShenawy H.M. & Eldin A.M., 2015. A comparative evaluation of low-level laser and topical steroid therapies for the treatment of erosive-atrophic lichen planus. Macedonian Journal of Medical Sciences, 3(3):462-466.

Othman N.A., Shaker O.G., Elshenawy H.M., Abd-Elmoniem W. & Eldin A.M., 2016. The effect of diode laser and topical steroid on serum level of TNF-alpha in oral lichen planus patients. Journal of Clinical and Experimental Dentistry, 8(5):566-570.

Jajarm H.H., Falaki F. & Mahdavi O., 2011. A comparative pilot study of low intensity laser versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus. Photomedicine and Laser Surgery, 29(6):421425.

ElShenawy H.M., Eldin A.M. & Nasry S.A., 2018. Management of pain in oral lichen planus patients: A comparative pilot study. Bulletin of National Research Centre, 42(1):15-21.

Jain R., Mhapuskar A.A., Prasad-Hiremutt D.R., Kale I. & Kalyanpur K., 2021. Efficacy of laser photobiomodulation compared to topical corticosteroids in the treatment of oral lichen planus: A randomized clinical trial. Journal of Oral pathology and Medicine, 47(1):111-117.

Ferri E.P., Barros-Gallo C., Abboud C.S., Yanaguizawa W.H. & Nunes F.D., 2018. Efficacy of photobiomodulation on oral lichen planus: A protocol study for a double-blind randomized controlled clinical trial. British Medical Journal, 8(1):240-251.